FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2980457711> ?p ?o ?g. }

• W2980457711 abstract "Abstract Abstract 404 To characterize the genomic events associated with distinct subtypes of AML, we used whole genome sequencing to compare 24 tumor/normal sample pairs from patients with normal karyotype (NK) M1-AML (12 cases) and t(15;17)-positive M3-AML (12 cases). All single nucleotide variants (SNVs), small insertions and deletions (indels), and cryptic structural variants (SVs) identified by whole genome sequencing (average coverage 28x) were validated using sample-specific custom Nimblegen capture arrays, followed by Illumina sequencing; an average coverage of 972 reads per somatic variant yielded 10,597 validated somatic variants (average 421/genome). Of these somatic mutations, 308 occurred in 286 unique genes; on average, 9.4 somatic mutations per genome had translational consequences. Several important themes emerged: 1) AML genomes contain a diverse range of recurrent mutations. We assessed the 286 mutated genes for recurrency in an additional 34 NK M1-AML cases and 9 M3-AML cases. We identified 51 recurrently mutated genes, including 37 that had not previously been described in AML; on average, each genome had 3 recurrently mutated genes (M1 = 3.2; M3 = 2.8, p = 0.32). 2) Many recurring mutations cluster in mutually exclusive pathways, suggesting pathophysiologic importance. The most commonly mutated genes were: FLT3 (36%), NPM1 (25%), DNMT3A (21%), IDH1 (18%), IDH2 (10%), TET2 (10%), ASXL1 (6%), NRAS (6%), TTN (6%), and WT1 (6%). In total, 3 genes (excluding PML-RARA) were mutated exclusively in M3 cases. 22 genes were found only in M1 cases (suggestive of alternative initiating mutations which occurred in methylation, signal transduction, and cohesin complex genes). 25 genes were mutated in both M1 and M3 genomes (suggestive of common progression mutations relevant for both subtypes). A single mutation in a cell growth/signaling gene occurred in 38 of 67 cases (FLT3, NRAS, RUNX1, KIT, CACNA1E, CADM2, CSMD1); these mutations were mutually exclusive of one another, and many of them occurred in genomes with PML-RARA, suggesting that they are progression mutations. We also identified a new leukemic pathway: mutations were observed in all four genes that encode members of the cohesin complex (STAG2, SMC1A, SMC3, RAD21), which is involved in mitotic checkpoints and chromatid separation. The cohesin mutations were mutually exclusive of each other, and collectively occur in 10% of non-M3 AML patients. 3) AML genomes also contain hundreds of benign “passenger” mutations. On average 412 somatic mutations per genome were translationally silent or occurred outside of annotated genes. Both M1 and M3 cases had similar total numbers of mutations per genome, similar mutation types (which favored C>T/G>A transitions), and a similar random distribution of variants throughout the genome (which was affected neither by coding regions nor expression levels). This is consistent with our recent observations of random “passenger” mutations in hematopoietic stem cell (HSC) clones derived from normal patients (Ley et al manuscript in preparation), and suggests that most AML-associated mutations are not pathologic, but pre-existed in the HSC at the time of initial transformation. In both studies, the total number of SNVs per genome correlated positively with the age of the patient (R2 = 0.48, p = 0.001), providing a possible explanation for the increasing incidence of AML in elderly patients. 4) NK M1 and M3 AML samples are mono- or oligo-clonal. By comparing the frequency of all somatic mutations within each sample, we could identify clusters of mutations with similar frequencies (leukemic clones) and determined that the average number of clones per genome was 1.8 (M1 = 1.5; M3 = 2.2; p = 0.04). 5) t(15;17) is resolved by a non-homologous end-joining repair pathway, since nucleotide resolution of all 12 t(15;17) breakpoints revealed inconsistent micro-homologies (0 – 7 bp). Summary: These data provide a genome-wide overview of NK and t(15;17) AML and provide important new insights into AML pathogenesis. AML genomes typically contain hundreds of random, non-genic mutations, but only a handful of recurring mutated genes that are likely to be pathogenic because they cluster in mutually exclusive pathways; specific combinations of recurring mutations, as well as rare and private mutations, shape the leukemia phenotype in an individual patient, and help to explain the clinical heterogeneity of this disease. Disclosures: Westervelt: Novartis: Speakers Bureau." @default.
• W2980457711 created "2019-10-25" @default.
• W2980457711 creator A5006502306 @default.
• W2980457711 creator A5007830810 @default.
• W2980457711 creator A5009112568 @default.
• W2980457711 creator A5013444791 @default.
• W2980457711 creator A5013993509 @default.
• W2980457711 creator A5014714324 @default.
• W2980457711 creator A5021913825 @default.
• W2980457711 creator A5022808238 @default.
• W2980457711 creator A5030586623 @default.
• W2980457711 creator A5033142370 @default.
• W2980457711 creator A5035432960 @default.
• W2980457711 creator A5036363023 @default.
• W2980457711 creator A5038288423 @default.
• W2980457711 creator A5041520404 @default.
• W2980457711 creator A5042552121 @default.
• W2980457711 creator A5046034812 @default.
• W2980457711 creator A5047326660 @default.
• W2980457711 creator A5049284725 @default.
• W2980457711 creator A5054198772 @default.
• W2980457711 creator A5054642128 @default.
• W2980457711 creator A5056864458 @default.
• W2980457711 creator A5056921013 @default.
• W2980457711 creator A5057508602 @default.
• W2980457711 creator A5061026009 @default.
• W2980457711 creator A5064410148 @default.
• W2980457711 creator A5064617740 @default.
• W2980457711 creator A5065066309 @default.
• W2980457711 creator A5068833334 @default.
• W2980457711 creator A5074942308 @default.
• W2980457711 creator A5076523265 @default.
• W2980457711 creator A5076598094 @default.
• W2980457711 creator A5078124570 @default.
• W2980457711 creator A5081851296 @default.
• W2980457711 creator A5082251778 @default.
• W2980457711 creator A5084251059 @default.
• W2980457711 creator A5084949368 @default.
• W2980457711 creator A5088266338 @default.
• W2980457711 creator A5089826284 @default.
• W2980457711 date "2011-11-18" @default.
• W2980457711 modified "2023-10-08" @default.
• W2980457711 title "Complete Sequencing and Comparison of 12 Normal Karyotype M1 AML Genomes with 12 t(15;17) Positive M3-APL Genomes" @default.
• W2980457711 doi "https://doi.org/10.1182/blood.v118.21.404.404" @default.
• W2980457711 hasPublicationYear "2011" @default.
• W2980457711 type Work @default.
• W2980457711 sameAs 2980457711 @default.
• W2980457711 citedByCount "1" @default.
• W2980457711 countsByYear W29804577112012 @default.
• W2980457711 crossrefType "journal-article" @default.
• W2980457711 hasAuthorship W2980457711A5006502306 @default.
• W2980457711 hasAuthorship W2980457711A5007830810 @default.
• W2980457711 hasAuthorship W2980457711A5009112568 @default.
• W2980457711 hasAuthorship W2980457711A5013444791 @default.
• W2980457711 hasAuthorship W2980457711A5013993509 @default.
• W2980457711 hasAuthorship W2980457711A5014714324 @default.
• W2980457711 hasAuthorship W2980457711A5021913825 @default.
• W2980457711 hasAuthorship W2980457711A5022808238 @default.
• W2980457711 hasAuthorship W2980457711A5030586623 @default.
• W2980457711 hasAuthorship W2980457711A5033142370 @default.
• W2980457711 hasAuthorship W2980457711A5035432960 @default.
• W2980457711 hasAuthorship W2980457711A5036363023 @default.
• W2980457711 hasAuthorship W2980457711A5038288423 @default.
• W2980457711 hasAuthorship W2980457711A5041520404 @default.
• W2980457711 hasAuthorship W2980457711A5042552121 @default.
• W2980457711 hasAuthorship W2980457711A5046034812 @default.
• W2980457711 hasAuthorship W2980457711A5047326660 @default.
• W2980457711 hasAuthorship W2980457711A5049284725 @default.
• W2980457711 hasAuthorship W2980457711A5054198772 @default.
• W2980457711 hasAuthorship W2980457711A5054642128 @default.
• W2980457711 hasAuthorship W2980457711A5056864458 @default.
• W2980457711 hasAuthorship W2980457711A5056921013 @default.
• W2980457711 hasAuthorship W2980457711A5057508602 @default.
• W2980457711 hasAuthorship W2980457711A5061026009 @default.
• W2980457711 hasAuthorship W2980457711A5064410148 @default.
• W2980457711 hasAuthorship W2980457711A5064617740 @default.
• W2980457711 hasAuthorship W2980457711A5065066309 @default.
• W2980457711 hasAuthorship W2980457711A5068833334 @default.
• W2980457711 hasAuthorship W2980457711A5074942308 @default.
• W2980457711 hasAuthorship W2980457711A5076523265 @default.
• W2980457711 hasAuthorship W2980457711A5076598094 @default.
• W2980457711 hasAuthorship W2980457711A5078124570 @default.
• W2980457711 hasAuthorship W2980457711A5081851296 @default.
• W2980457711 hasAuthorship W2980457711A5082251778 @default.
• W2980457711 hasAuthorship W2980457711A5084251059 @default.
• W2980457711 hasAuthorship W2980457711A5084949368 @default.
• W2980457711 hasAuthorship W2980457711A5088266338 @default.
• W2980457711 hasAuthorship W2980457711A5089826284 @default.
• W2980457711 hasConcept C104317684 @default.
• W2980457711 hasConcept C119054055 @default.
• W2980457711 hasConcept C135763542 @default.
• W2980457711 hasConcept C141231307 @default.
• W2980457711 hasConcept C153209595 @default.
• W2980457711 hasConcept C192953774 @default.
• W2980457711 hasConcept C21790070 @default.
• W2980457711 hasConcept C24432333 @default.
• W2980457711 hasConcept C2781187634 @default.
• W2980457711 hasConcept C501734568 @default.
• W2980457711 hasConcept C51679486 @default.
• W2980457711 hasConcept C54355233 @default.

• next